{"DataElement":{"publicId":"2854873","version":"1","preferredName":"Chronic Graft Versus Host Disease Diagnosis Severity Type","preferredDefinition":"Text term to describe the intensity or severity of chronic Graft vs. Host Disease (GVHD) organ involvement at the time of diagnosis.","longName":"CGVHD_DX_SVRTY_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2854871","version":"1","preferredName":"Chronic Graft Versus Host Disease Diagnosis Severity","preferredDefinition":"information related to the severity of graft versus host disease following transplant._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"CGVHD_DX_SVRTY","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2512832","version":"1","preferredName":"Chronic Graft Versus Host Disease","preferredDefinition":"A graft versus host disease with symptoms appearing more than 100 days post-transplant.","longName":"C4981","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B8985BC-2113-374B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2854869","version":"1","preferredName":"Diagnosis Severity","preferredDefinition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.:Severity; used of the degree of something undesirable e.g. pain or weather.","longName":"C15220:C25676","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Severity","conceptCode":"C25676","definition":"Used of the degree of something undesirable e.g. pain or weather; also, strictness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65C9E4D1-CC3A-C2BB-E040-BB89AD430C4B","latestVersionIndicator":"Yes","beginDate":"2009-03-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-03-23","modifiedBy":"ONEDATA","dateModified":"2009-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65C9E4D1-CC4B-C2BB-E040-BB89AD430C4B","latestVersionIndicator":"Yes","beginDate":"2009-03-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-03-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2795869","version":"1","preferredName":"Graft Versus Host Disease Severity Type","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Used of the degree of something undesirable e.g. pain or weather; also, strictness._Type; a subdivision of a particular kind of thing.","longName":"GVHD_SV_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Severe","valueDescription":"Severe","ValueMeaning":{"publicId":"2955376","version":"1","preferredName":"Severe","longName":"2955376","preferredDefinition":"Signs and symptoms of chronic GVHD limit function substantially despite appropriate therapy or are progressive through second line therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"767278B8-77EB-4D95-E040-BB89AD4364D6","latestVersionIndicator":"Yes","beginDate":"2009-10-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"767278B8-7803-4D95-E040-BB89AD4364D6","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"Mild","valueDescription":"Mild","ValueMeaning":{"publicId":"2955374","version":"1","preferredName":"Mild","longName":"2955374","preferredDefinition":"Signs and symptoms of chronic GVHD do not interfere substantially with function and do not progress once appropriately treated with local therapy or standard systemic therapy (corticosteroids and/or cyclosporine or FK 506)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"767278B8-77A7-4D95-E040-BB89AD4364D6","latestVersionIndicator":"Yes","beginDate":"2009-10-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"767278B8-77BF-4D95-E040-BB89AD4364D6","beginDate":"2008-10-31","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"Moderate","valueDescription":"Moderate","ValueMeaning":{"publicId":"2955375","version":"1","preferredName":"Moderate","longName":"2955375","preferredDefinition":"Signs and symptoms of chronic GVHD interfere somewhat with function despite appropriate therapy or are progressive through first line systemic therapy (corticosteroids and/or cyclosporine or FK 506)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"767278B8-77C9-4D95-E040-BB89AD4364D6","latestVersionIndicator":"Yes","beginDate":"2009-10-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"767278B8-77E1-4D95-E040-BB89AD4364D6","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"No GVHD","valueDescription":"Negation Graft Versus Host Disease","ValueMeaning":{"publicId":"5580503","version":"1","preferredName":"Negation Graft Versus Host Disease","longName":"5580503","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41D13E08-B33D-2E95-E053-F662850ACE8B","latestVersionIndicator":"Yes","beginDate":"2016-11-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"41D13E08-B356-2E95-E053-F662850ACE8B","beginDate":"2016-11-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-21","modifiedBy":"ONEDATA","dateModified":"2016-11-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2795868","version":"1","preferredName":"Graft Versus Host Disease Severity Type","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:Severity; used of the degree of something undesirable e.g. pain or weather.:Type; a subdivision of a particular kind of thing.","longName":"C3063:C25676:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Severity","conceptCode":"C25676","definition":"Used of the degree of something undesirable e.g. pain or weather; also, strictness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A670340-59A4-1796-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-29","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-10-29","modifiedBy":"ONEDATA","dateModified":"2008-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A670340-59B5-1796-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-29","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-10-29","modifiedBy":"CCURATOR","dateModified":"2023-12-21","changeDescription":". Added PV &#34;No GVHD&#34; for MC. AK 11/21/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Severity of cGVHD organ invol","type":"Preferred Question Text","description":"Severity of cGVHD organ involvement at diagnosis","url":null,"context":"CCR"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Overall Chronic GVHD Severity:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"65C9E4D1-CC5C-C2BB-E040-BB89AD430C4B","latestVersionIndicator":"Yes","beginDate":"2009-03-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-03-23","modifiedBy":"MAESKEB","dateModified":"2022-03-31","changeDescription":"Curated to support CCR Transplant study 08C0097.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}